Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers

Trial Profile

Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs 2X 121 (Primary) ; Carboplatin (Primary) ; Eribulin (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 30 Mar 2015 Planned initiation date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 27 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top